APLS Stock Sees Surge of Approximately 1.03% in Last Five Days

CHWY Stock

Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Apellis Pharmaceuticals Inc shares valued at $268,492 were sold by Francois Cedric on Feb 12. At $67.77 per share, Francois Cedric sold 3,962 shares. The insider’s holdings dropped to 313,662 shares worth approximately $21.14 million following the completion of this transaction.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Also, Sullivan Timothy Eugene sold 1,431 shares, netting a total of over 96,974 in proceeds. Following the sale of shares at $67.77 each, the insider now holds 93,338 shares.

Before that, Deschatelets Pascal had sold 1,148 shares from its account. In a trade valued at $77,796, the Chief Scientific Officer traded Apellis Pharmaceuticals Inc shares for $67.77 each. Upon closing the transaction, the insider’s holdings decreased to 1,148 shares, worth approximately $75.21 million.

As published in a research note from Jefferies on February 05, 2024, Apellis Pharmaceuticals Inc [APLS] has been rated up from a Hold to a Buy and the price target has been revised to $80 from $68.

Analyzing APLS Stock Performance

During the last five days, there has been a surge of approximately 1.03%. Over the course of the year, Apellis Pharmaceuticals Inc shares have jumped approximately 12.58%. Shares of the company reached a 52-week high of $73.80 on 01/09/24 and a 52-week low of $58.57 on 01/08/24. A 50-day SMA is recorded $63.41, while a 200-day SMA reached $58.99. Nevertheless, trading volume fell to 1.16 million shares from 1.3 million shares the previous day.

Support And Resistance Levels for Apellis Pharmaceuticals Inc (APLS)

According to the 24-hour chart, there is a support level at 66.34, which, if violated, would cause prices to drop to 65.29. In the upper region, resistance lies at 68.34. The next price resistance is at 69.29. RSI (Relative Strength Index) is 55.11 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 1.14, which suggests the price will increase in the coming days. Percent R is at 22.59%, indicating bullish price movement. Stochastics %K at holding indicates that the stock is to be held.

Is Apellis Pharmaceuticals Inc subject to short interest?

Stocks of Apellis Pharmaceuticals Inc saw a sharp steep in short interest on Jan 31, 2024 dropping by -1.02 million shares to 10.67 million. Data from Yahoo Finance shows that the short interest on Dec 29, 2023 was 11.69 million shares. A decline of -9.56% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 5.58 of the overall float, the days-to-cover ratio (short ratio) decline to 5.58.

Most Popular